Go Pro
NASDAQ:NTHI

Neonc Technologies Q2 2026 Earnings Report

Neonc Technologies logo
$4.22 +1.01 (+31.46%)
Closing price 04:00 PM Eastern
Extended Trading
$4.18 -0.04 (-0.83%)
As of 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Neonc Technologies EPS Results

Actual EPS
-$0.58
Consensus EPS
-$0.12
Beat/Miss
Missed by -$0.46
One Year Ago EPS
N/A

Neonc Technologies Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Neonc Technologies Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Monday, August 10, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

Neonc Technologies' Q3 2026 earnings is estimated for Friday, August 14, 2026, based on past reporting schedules

Neonc Technologies Earnings Headlines

The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.tc pixel
See More Neonc Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Neonc Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neonc Technologies and other key companies, straight to your email.

About Neonc Technologies

Neonc Technologies (NASDAQ:NTHI) develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.

View Neonc Technologies Profile